Cassava Sciences Phase 3 Data Falls Short in Alzheimer’s Study
Disappointing Results for Alzheimer’s Drug Simufilam Introduction: Cassava Sciences Phase 3 Data Cassava Sciences, Inc. recently announced the topline results from its Phase 3 ReThink-ALZ study of simufilam, a potential treatment for Alzheimer’s disease. Unfortunately, the data did not meet the co-primary endpoints, raising concerns about the drug’s efficacy. Cassava Sciences’ Phase 3 ReThink-ALZ study … Read more